Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953526 | 1.00 | MAPT (0.63) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL27984493 | 0.82 | MAPT (0.70) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL7315076 | 0.81 | NPC1 (0.63) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| Benzene SCHEMBL6030702 | 0.80 | MAPT (0.61) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL28882874 | 0.80 | NPC1 (0.61) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL2125044 | 0.79 | MAPT (0.70) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL9848762 | 0.79 | NPC1 (0.70) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL1420033 | 0.78 | TP53 (0.81) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL155002 | 0.78 | MAPT (1.00) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL28518705 | 0.77 | MAPT (0.58) | MAPTNPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1391456-B1 | 2-IMINOIMIDAZOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7476688-B2 | Cyclic amidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-13 | — | — | US | disclosed |
| US-7304083-B2 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| EP-1614680-A2 | Process for preparing 2-iminopyrrolidine derivatives | Eisai Co., Ltd. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040254376-A1 | Cyclic amidine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1394152-A1 | 2-IMINOIMIDAZOLE DERIVATIVES (1) | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1391456-A1 | 2-IMINOIMIDAZOLE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1386912-A1 | CYCLIC AMIDINE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-6384065-B1 | CONTROL THE FUNCTIONS OF PROTEINS SUCH AS ENZYMES AND RECEPTOR FORTREATING INFLAMMATORY DISEASES SUCH AS RHEUMATOID ARTHRITIS, | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | H1-2, H1-3, H1-4 | MAPT 3908/4885NPC1 4029/4885RAB9A 2353/4885 |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | MAPT 3483/4885NPC1 4243/4885RAB9A 429/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | MAPT 3440/4885NPC1 4254/4885RAB9A 418/4885 |
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | H1-2, H1-0, H1-3 | MAPT 4077/4885NPC1 3254/4885RAB9A 1696/4885 |
| US-20040254376-A1 | Cyclic amidine derivative | ARGLU1, ARG1, PRMT1 | MAPT 4592/4885NPC1 2685/4885RAB9A 445/4885 |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | H1-10, H1-3, H1-4 | MAPT 4417/4885NPC1 3249/4885RAB9A 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.